143 related articles for article (PubMed ID: 35282894)
1. Successful treatment with ixekizumab of lower-limb linear psoriasis in a child.
Pourchot D; Mery-Bossard L; Petitjean B; Mahé E; Thomas-Beaulieu D
Ann Dermatol Venereol; 2022 Sep; 149(3):216-218. PubMed ID: 35282894
[No Abstract] [Full Text] [Related]
2. Ixekizumab for the treatment of psoriasis: up-to-date.
Craig S; Warren RB
Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
[No Abstract] [Full Text] [Related]
3. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.
Giunta A; Ventura A; Chimenti MS; Bianchi L; Esposito M
Drug Des Devel Ther; 2017; 11():1643-1651. PubMed ID: 28652702
[TBL] [Abstract][Full Text] [Related]
4. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
5. The successful treatment with ixekizumab in a multi-failure psoriasis patient.
Azevedo A; Torres T
Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677837
[TBL] [Abstract][Full Text] [Related]
6. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
7. A case of pediatric psoriasis successfully and rapidly treated with ixekizumab.
Megna M; Fornaro L; De Lucia M; Rescigno O; Camela E; Fabbrocini G
Dermatol Ther; 2021 Nov; 34(6):e15108. PubMed ID: 34427377
[No Abstract] [Full Text] [Related]
8. A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
Peranteau AJ; Turkeltaub AE; Tong Y; Nawas Z; Tyring SK
Skin Therapy Lett; 2016 Nov; 21(6):1-6. PubMed ID: 27825174
[TBL] [Abstract][Full Text] [Related]
9. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
Georgakopoulos JR; Phung M; Ighani A; Yeung J
J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
[TBL] [Abstract][Full Text] [Related]
10. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
Kimura R; Sugita K; Yamamoto O
Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
[No Abstract] [Full Text] [Related]
11. Successful response of genital psoriasis to ixekizumab: report of six cases.
García-Legaz Martínez M; Martínez-Doménech Á; Hernández-Bel P; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Sánchez-Carazo JL; Alegre-de Miquel V; Pérez-Ferriols A
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):e325-e327. PubMed ID: 30980763
[No Abstract] [Full Text] [Related]
12. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.
Griffiths CEM; Fava M; Miller AH; Russell J; Ball SG; Xu W; Acharya N; Rapaport MH
Psychother Psychosom; 2017; 86(5):260-267. PubMed ID: 28903122
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
[TBL] [Abstract][Full Text] [Related]
15. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
[TBL] [Abstract][Full Text] [Related]
16. Educational service correlates with greater improvement and adherence in psoriasis patients responding to ixekizumab.
Hu K; Shen M; Zhang M; Kuang Y
J Dtsch Dermatol Ges; 2023 Aug; 21(8):900-902. PubMed ID: 37480160
[No Abstract] [Full Text] [Related]
17. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
Blegvad C; Skov L; Zachariae C
Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
[No Abstract] [Full Text] [Related]
18. Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors.
Yeung J; Vender R; Turchin I; Shukla R; Maari C; Hong CH; Barakat M; Lansang P
J Am Acad Dermatol; 2021 Apr; 84(4):1169-1171. PubMed ID: 33221464
[No Abstract] [Full Text] [Related]
19. Ixekizumab in the treatment of psoriatic arthritis.
Lespessailles E; Toumi H
Immunotherapy; 2021 Jan; 13(1):19-33. PubMed ID: 33167745
[TBL] [Abstract][Full Text] [Related]
20. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
Kimmel G; Chima M; Kim HJ; Bares J; Yao CJ; Singer G; Kim SJ; Bagel J; Lebwohl M
J Am Acad Dermatol; 2019 Sep; 81(3):857-859. PubMed ID: 31078609
[No Abstract] [Full Text] [Related]
[Next] [New Search]
